ES2638821T3 - Un punto de corte en la expresión de la proteína PTEN que identifica tumores con precisión y es predictivo de la respuesta a fármacos a un inhibidor pan-ErbB - Google Patents

Un punto de corte en la expresión de la proteína PTEN que identifica tumores con precisión y es predictivo de la respuesta a fármacos a un inhibidor pan-ErbB Download PDF

Info

Publication number
ES2638821T3
ES2638821T3 ES11700467.1T ES11700467T ES2638821T3 ES 2638821 T3 ES2638821 T3 ES 2638821T3 ES 11700467 T ES11700467 T ES 11700467T ES 2638821 T3 ES2638821 T3 ES 2638821T3
Authority
ES
Spain
Prior art keywords
pten
protein expression
pan
cell
pten protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11700467.1T
Other languages
English (en)
Spanish (es)
Inventor
Christina Marie Coughlin
Anna Berkenblit
Jay Marshall Feingold
Daniel Stephen Johnston
Andrew Louis Strahs
Charles Michael Zacharchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2638821T3 publication Critical patent/ES2638821T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES11700467.1T 2010-01-13 2011-01-04 Un punto de corte en la expresión de la proteína PTEN que identifica tumores con precisión y es predictivo de la respuesta a fármacos a un inhibidor pan-ErbB Active ES2638821T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29461510P 2010-01-13 2010-01-13
US294615P 2010-01-13
PCT/US2011/020080 WO2011087926A1 (en) 2010-01-13 2011-01-04 A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR

Publications (1)

Publication Number Publication Date
ES2638821T3 true ES2638821T3 (es) 2017-10-24

Family

ID=43569472

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11700467.1T Active ES2638821T3 (es) 2010-01-13 2011-01-04 Un punto de corte en la expresión de la proteína PTEN que identifica tumores con precisión y es predictivo de la respuesta a fármacos a un inhibidor pan-ErbB

Country Status (6)

Country Link
US (1) US8338456B2 (cg-RX-API-DMAC10.html)
EP (1) EP2524231B1 (cg-RX-API-DMAC10.html)
JP (2) JP6126382B2 (cg-RX-API-DMAC10.html)
CA (1) CA2787048C (cg-RX-API-DMAC10.html)
ES (1) ES2638821T3 (cg-RX-API-DMAC10.html)
WO (1) WO2011087926A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN104010494B (zh) * 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
CA2883356A1 (en) * 2012-08-30 2014-03-06 Turun Yliopisto Method of selecting individualized brain cancer therapy
US20200157563A1 (en) * 2017-07-18 2020-05-21 The Broad Institute, Inc. Methods of producing human cancer cell models and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291736A1 (en) * 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1756137A4 (en) 2003-11-05 2007-10-31 Univ Texas DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
WO2006044748A2 (en) * 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2006116016A2 (en) * 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8700335B2 (en) * 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2553390T3 (es) * 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
BRPI0911451A2 (pt) * 2008-05-25 2019-09-24 Wyeth Llc biomarcadores para eficácia medicamentosa de egfr/her/erb
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Also Published As

Publication number Publication date
CA2787048C (en) 2021-06-22
JP2013517476A (ja) 2013-05-16
CA2787048A1 (en) 2011-07-21
EP2524231B1 (en) 2017-06-28
US8338456B2 (en) 2012-12-25
JP6126382B2 (ja) 2017-05-10
JP2016053579A (ja) 2016-04-14
WO2011087926A1 (en) 2011-07-21
US20120010240A1 (en) 2012-01-12
EP2524231A1 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
Paccez et al. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
CA2787048C (en) A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor
Wang et al. CHIP is a novel tumor suppressor in pancreatic cancer and inhibits tumor growth through targeting EGFR
Hastak et al. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly (ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin
Tamborini et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas
Barnabas et al. Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines
Mo et al. S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer
Cirak et al. Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis
Stern et al. PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance
US20220170107A1 (en) Phosphatidylinositol-3-kinase pathway biomarkers
Liu et al. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
Lee et al. Role of erbB3 receptors in cancer therapeutic resistance
El-Guindy et al. Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival
Shimura et al. Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas
Matsuzaki et al. Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives
Li et al. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2
Yi et al. Ribosomal protein L22‐like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway
Chudasama et al. Targeting fibroblast growth factor receptor 1 for treatment of soft-tissue sarcoma
Sawant et al. Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor
Schieffer et al. YAP1-FAM118B fusion defines a rare subset of childhood and young adulthood meningiomas
Miller et al. ErbB-2 signaling in advanced prostate cancer progression and potential therapy
Sun et al. TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC
Lyu et al. The erbB3-and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells
Qiu et al. MNAT1 promotes proliferation and the chemo-resistance of osteosarcoma cell to cisplatin through regulating PI3K/Akt/mTOR pathway
Lombardi et al. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer